Related Experiment Videos

High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma

S Schuh1, P Parkin, A Rajan

  • 1Department of Paediatrics, Hospital for Sick Children, Toronto, Canada.

Pediatrics
|April 1, 1989
PubMed

Insights

High-dose nebulized albuterol (albuterol sulfate) is safe and effective for severe acute asthma in children. This treatment significantly improved lung function and reduced hospitalizations compared to low-dose albuterol.

Area of Science:

  • Pediatric Pulmonology
  • Emergency Medicine
  • Pharmacology

Background:

  • Severe, acute asthma is a common pediatric emergency.
  • Optimal dosing of nebulized albuterol for severe pediatric asthma remains under investigation.

Purpose of the Study:

  • To compare the efficacy and safety of high-dose versus low-dose nebulized albuterol in children with severe, acute asthma.

Main Methods:

  • Thirty-two children (5-17 years) with severe, acute asthma were randomized.
  • Participants received either high-dose (0.15 mg/kg) or low-dose (0.05 mg/kg) nebulized albuterol every 20 minutes for six doses.

Main Results:

  • The high-dose albuterol group showed significantly greater improvement in lung function (FEV1, FVC) and wheeze scores.
  • Hospitalization rates were lower in the high-dose group.
  • Adverse events (tremor, hyperactivity, vomiting) and vital sign changes were similar between groups.

Conclusions:

  • High-dose, frequently administered nebulized albuterol is a safe and effective treatment for severe, acute pediatric asthma.
  • This regimen offers improved clinical outcomes without increased adverse effects.

Related Concept Videos